13 July 2023 - Conditional approval based on data from Phase 3 PROpel trial.
Health Canada has granted a Notice of Compliance with Conditions for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated.